Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Open accessThe DOI matches its Crossref record; 189 of the 190 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Polycystic ovary syndrome (PCOS) is characterized by elevated androgen production and subclinical changes in cardiovascular and metabolic risk markers. Total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose, and fasting insulin appear to increase specifically in PCOS compared with fertile women. PCOS also confers an increased risk of cardiometabolic disease in later life. Novel biomarkers such as serum’s cholesterol efflux capacity and blood-derived macrophage activation profile may assist in more accurately defining the cardiometabolic risk profile in these women. Aldosterone antagonists, androgen receptor antagonists, 5α-reductase inhibitors, and synthetic progestogens are used to reduce hyperandrogenism. Because increased insulin secretion enhances ovarian androgen production, short-term treatment with metformin and other hypoglycemic agents results in significant weight loss, favorable metabolic changes, and testosterone reduction. The naturally occurring inositols display insulin-sensitizing effects and may be also used in this context because of their safety profile. Combined oral contraceptives represent the drug of choice for correction of androgen-related symptoms. Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. While new options are adding to established therapeutic approaches, a sometimes difficult balance between efficacy and safety of available medications has to be found in individual women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unfortunately, the available studies refer only to short-term evaluations and the results are discordant [48].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“Additional studies showed that MYO concentration in the follicular fluid was directly correlated with high oocyte quality [99] and that MYO supplementation improved oocyte and embryo quality and reduced the amount of recombinant FSH administered during ovarian stimulation protocols [100,101].”
BackgroundRetracted- Retracted
- Retracted
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Irrespective of weight loss, metformin does ameliorate glucose tolerance and reduce insulin levels when associated with lifestyle modification [80]; however, these positive effects are rapidly lost within the first year after its discontinuation, stressing again the need to adopt healthy habits in order to reduce long…”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Insulin has a gonadotropin-like action and may increase androgen production, which contributes to worsening both metabolic impairment and clinical picture [8].”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160548.78317.29 · Cited by 1,854 · cited 1×
“Increased arterial stiffness, a parameter independent of age and systolic blood pressure, implies a possible direct effect of PCOS components on the vascular wall [60,61].”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 1×
“Therefore, stimulation of the ATP-binding cassette transporter-A1 (ABCA1)-dependent cholesterol efflux from macrophage cells to HDL, rather than HDL cholesterol (HDL-C) levels per se, was found to be inversely associated with the incidence of atherothrombotic CV events [16,17].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · cited 2×
“As the tight link between obesity, IR/hyperinsulinism, and increased cardiometabolic risk is well known, the role of hyperandrogenism in dyslipidemia, diabetes, and CV disease (CVD) remains difficult to interpret [27].”
BackgroundPasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“Despite having virtually no effect on BMI, metformin was associated with mild weight loss in some trials [77,78]; note that it did not produce further improvement in weight in patients already on diet and exercise programs [79].”
BackgroundNauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
McCartney, C. R., & Marshall, J. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1514916 · Cited by 581
Menstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“were the first to report DCI efficacy in the treatment of obese PCOS women for 6–8 weeks, demonstrating improved insulin sensitivity, ovulatory function, and hyperandrogenism and decreased blood pressure levels and plasma TG concentrations [94].”
BackgroundMartin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Mortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up
Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00035-3 · Cited by 504
Saleheen, D., Scott, R., Javad, S., Zhao, W., Rodrigues, A., Picataggi, A., Lukmanova, D., Mucksavage, M. L., Luben, R., Billheimer, J., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00126-6 · Cited by 470
Osibogun, O., Ogunmoroti, O., & Michos, E. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.010 · Cited by 423 · cited 2×
“Considering that PCOS women frequently present increased TG and low HDL-C levels, associated with IR, obesity and hyperandrogenism [5], the Endocrine Society guidelines recommend screening all PCOS women routinely for dyslipidemia [75].”
BackgroundCombined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813.pub2 · Cited by 399
The use of ketoconazole as an inhibitor of steroid production
Oates, J. A., Wood, A. J. J., & Sonino, N. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171307 · Cited by 395 · cited 1×
“In vivo and in vitro studies showed that this agent acts as a potent inhibitor of both gonadal and adrenal steroidogenesis [63].”
BackgroundHepatic Injury Associated With Ketoconazole Therapy
Lewis, J. H., Zimmerman, H. J., Benson, G. D., & Ishak, K. G. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80021-9 · Cited by 394
Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome
Hahn, S., Janssen, O. E., Tan, S., Pleger, K., Mann, K., Schedlowski, M., Kimmig, R., Benson, S., Balamitsa, E., & Elsenbruch, S. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02024 · Cited by 387
Tang, T., Norman, R. J., Balen, A. H., & Lord, J. M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053 · Cited by 369
Goodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dscpt2 · Cited by 359
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
Cena, H., Chiovato, L., & Nappi, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa285 · Cited by 356
Martin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339
Kalra, S. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0089-4 · Cited by 338
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334 · cited 1×
“Despite having virtually no effect on BMI, metformin was associated with mild weight loss in some trials [77,78]; note that it did not produce further improvement in weight in patients already on diet and exercise programs [79].”
BackgroundBirdsall, M. A., Farquhar, C. M., & White, H. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-1-199701010-00005 · Cited by 327 · cited 1×
“Considerable evidence shows that androgens play a pivotal role in gender-associated differences in blood pressure (BP) regulation, and several experimental models showed that androgens can promote hypertension [45,46].”
BackgroundHolman, R. R., Coleman, R. L., Chan, J. C. N., Chiasson, J.-L., Feng, H., Ge, J., Gerstein, H. C., Gray, R., Huo, Y., Lang, Z., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30309-1 · Cited by 323
D‐Chiro‐Inositol – Its Functional Role in Insulin Action and its Deficit in Insulin Resistance
Larner, J. (2002) · Journal of Diabetes Research · doi:10.1080/15604280212528 · Cited by 277
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Resident and Monocyte-Derived Macrophages in Cardiovascular Disease
Honold, L., & Nahrendorf, M. (2018) · Circulation Research · doi:10.1161/circresaha.117.311071 · Cited by 274
Diamanti-Kandarakis, E., Paterakis, T., Alexandraki, K., Piperi, C., Aessopos, A., Katsikis, I., Katsilambros, N., Kreatsas, G., & Panidis, D. (2006) · Human Reproduction · doi:10.1093/humrep/del003 · Cited by 258
Brettenthaler, N., De Geyter, C., Huber, P. R., & Keller, U. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031737 · Cited by 247
Legro, R. S., Dodson, W. C., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Fleming, J., Allison, K. C., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2778 · Cited by 242
Morin-Papunen, L. C., Vauhkonen, I., Koivunen, R. M., Ruokonen, A., Martikainen, H. K., & Tapanainen, J. S. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6792 · Cited by 235
Rice, S., Christoforidis, N., Gadd, C., Nikolaou, D., Seyani, L., Donaldson, A., Margara, R., Hardy, K., & Franks, S. (2005) · Human Reproduction · doi:10.1093/humrep/deh609 · Cited by 229
Dumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
The Use of Sex-Specific Factors in the Assessment of Women’s Cardiovascular Risk
Agarwala, A., Michos, E. D., Samad, Z., Ballantyne, C. M., & Virani, S. S. (2020) · Circulation · doi:10.1161/circulationaha.119.043429 · Cited by 217
Gambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 1×
“On the other hand, several authors showed that FLU was not very effective in improving IR, when administered alone, while if associated with metformin, a well-known insulin-sensitizing drug, FLU significantly improves both IR indices and visceral adipose distribution, mobilizing visceral fat at abdominal level, and fi…”
BackgroundMoghetti, P., Tosi, F., Tosti, A., Negri, C., Misciali, C., Perrone, F., Caputo, M., Muggeo, M., & Castello, R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6245 · Cited by 201
Fuhrmann, U., Krattenmacher, R., Slater, E. P., & Fritzemeier, K.-H. (1996) · Contraception · doi:10.1016/s0010-7824(96)00195-3 · Cited by 197
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne
Brown, J., Farquhar, C., Lee, O., Toomath, R., & Jepson, R. G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000194.pub2 · Cited by 196
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188 · cited 1×
“All these effects have been subsequently confirmed in lean PCOS women [95].”
BackgroundHormonal contraceptives: pharmacology tailored to women's health
De Leo, V., Musacchio, M. C., Cappelli, V., Piomboni, P., & Morgante, G. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw016 · Cited by 188
Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Domecq, J. P., Prutsky, G., Mullan, R. J., Hazem, A., Sundaresh, V., Elamin, M. B., Phung, O. J., Wang, A., Hoeger, K., Pasquali, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2385 · Cited by 184 · cited 1×
“Irrespective of weight loss, metformin does ameliorate glucose tolerance and reduce insulin levels when associated with lifestyle modification [80]; however, these positive effects are rapidly lost within the first year after its discontinuation, stressing again the need to adopt healthy habits in order to reduce long…”
BackgroundPharmacodynamics and pharmacokinetics of inositol(s) in health and disease
Bizzarri, M., Fuso, A., Dinicola, S., Cucina, A., & Bevilacqua, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1206887 · Cited by 183
Chiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182
Cusan, L., Dupont, A., Gomez, J.-L., Tremblay, R. R., & Labrie, F. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56518-2 · Cited by 178
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175
The Impact of Obesity on the Incidence of Type 2 Diabetes Among Women With Polycystic Ovary Syndrome
Kakoly, N. S., Earnest, A., Teede, H. J., Moran, L. J., & Joham, A. E. (2019) · Diabetes Care · doi:10.2337/dc18-1738 · Cited by 174 · cited 12×
“DPP4-Is can be therefore considered as an alternative option in metformin-intolerant women with IGT or T2DM due to their safety profile and convenient administration route [146].”
BackgroundInfluentialMoghetti, P. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.89 · Cited by 168
Vascular reactivity is impaired in genetic females taking high-dose androgens
McCredie, R. J., McCrohon, J. A., Turner, L., Griffiths, K. A., Handelsman, D. J., & Celermajer, D. S. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00416-1 · Cited by 166
Diamanti-Kandarakis, E., Mitrakou, A., Raptis, S., Tolis, G., & Duleba, A. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5041 · Cited by 158
Arlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Morin-Papunen, L. C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3161 · Cited by 157
Venturoli, S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1304 · Cited by 152
Liu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 148
Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., & Nestler, J. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1070 · Cited by 146
The D-chiro-inositol paradox in the ovary
Carlomagno, G., Unfer, V., & Roseff, S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.027 · Cited by 139
Cardiovascular disease risk in women with PCOS
Dokras, A. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.009 · Cited by 132
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Sharpe, A., Morley, L. C., Tang, T., Norman, R. J., & Balen, A. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013505 · Cited by 132
Spironolactone as a single agent for long‐term therapy of hirsute patients
Spritzer, P. M., Lisboa, K. O., Mattiello, S., & Lhullier, F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00982.x · Cited by 123
Toniolo, A., Fadini, G. P., Tedesco, S., Cappellari, R., Vegeto, E., Maggi, A., Avogaro, A., Bolego, C., & Cignarella, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2751 · Cited by 123
Self-citationJaved, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome
Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Colao, A., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0399 · Cited by 120
Prolonged Treatment of Cushing's Disease by Ketoconazole
SONINO, N., BOSCARO, M., & MANTERO, F. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-4-718 · Cited by 114
The influence of female sex steroids on glucose metabolism and insulin action.
Godsland, I. F. (1996) · PubMed · Cited by 112
Glueck, C. J. (2003) · Human Reproduction · doi:10.1093/humrep/deg343 · Cited by 111
Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.
Shet, M. S., McPhaul, M. J., Fisher, C., Stallings, N. R., & Estabrook, R. W. (1997) · PubMed · Cited by 110
Ibáñez, L., & de Zegher, F. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi054 · Cited by 108
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106 · cited 2×
“The consequent MYO deficiency in the ovary might be involved in the impaired FSH signaling and poor oocyte quality observed in PCOS [89].”
BackgroundPsychological well-being and sexarche in women with polycystic ovary syndrome
de Niet, J. E., de Koning, C. M., Pastoor, H., Duivenvoorden, H. J., Valkenburg, O., Ramakers, M. J., Passchier, J., de Klerk, C., & Laven, J. S. E. (2010) · Human Reproduction · doi:10.1093/humrep/deq068 · Cited by 103 · cited 1×
“However, the improvement or correction of hyperandrogenism has always been considered as a second-line therapeutic goal with respect to fertility or obesity, even though in real clinical practice the psychological consequences of dermatological signs associated with higher androgen levels are recognized [30,31].”
BackgroundA review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 103
Halperin, I. J., Sujana Kumar, S., Stroup, D. F., & Laredo, S. E. (2011) · Human Reproduction · doi:10.1093/humrep/deq301 · Cited by 102
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
(2011) · PubMed · Cited by 91
Insulin Mediators and the Mechanism of Insulin Action
Romero, G. G., & Larner, J. (1993) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60932-1 · Cited by 90
Rasmussen, C. B., & Lindenberg, S. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00140 · Cited by 90
Donà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89
Self-citationPaul, C., Laganà, A. S., Maniglio, P., Triolo, O., & Brady, D. M. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2016.1144741 · Cited by 89
Ortega-González, C., Cardoza, L., Coutiño, B., Hidalgo, R., Arteaga-Troncoso, G., & Parra, A. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05844 · Cited by 83
Macrophage Function and Polarization in Cardiovascular Disease: A Role of Estrogen Signaling?
Bolego, C., Cignarella, A., Staels, B., & Chinetti-Gbaguidi, G. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301328 · Cited by 83
Self-citationInsulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome
Palomba, S., Falbo, A., Russo, T., Manguso, F., Tolino, A., Zullo, F., De Feo, P., & Orio, F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0441 · Cited by 82
Hormonal contraception and thrombosis
Sitruk-Ware, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.08.039 · Cited by 79
Xu, Y., Wu, Y., & Huang, Q. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4480-z · Cited by 78
Baillargeon, J.-P., Nestler, J. E., Ostlund, R. E., Apridonidze, T., & Diamanti-Kandarakis, E. (2008) · Human Reproduction · doi:10.1093/humrep/den097 · Cited by 77
Diabetes Mellitus Secondary to Cushing’s Disease
Barbot, M., Ceccato, F., & Scaroni, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00284 · Cited by 75
Self-citationZwadlo, C., Schmidtmann, E., Szaroszyk, M., Kattih, B., Froese, N., Hinz, H., Schmitto, J. D., Widder, J., Batkai, S., Bähre, H., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012066 · Cited by 74
Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
Penna, I. A. A., Canella, P. R. B., Reis, R. M., Silva de Sá, M. F., & Ferriani, R. A. (2005) · Human Reproduction · doi:10.1093/humrep/dei104 · Cited by 72
Treatment of hirsutism in women with flutamide
Marcondes, J. A. M., Minanni, S. L., Luthold, W. W., WAJCHENBERG, B. L., SAMOJLIK, E., & Kirschner, M. A. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54897-3 · Cited by 70
Agrawal, A., Mahey, R., Kachhawa, G., Khadgawat, R., Vanamail, P., & Kriplani, A. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1549656 · Cited by 70
Decreased Cholesterol Efflux Capacity and Atherogenic Lipid Profile in Young Women With PCOS
Roe, A., Hillman, J., Butts, S., Smith, M., Rader, D., Playford, M., Mehta, N. N., & Dokras, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3918 · Cited by 69
Dokras, A. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.027 · Cited by 68
Long-term consequences of polycystic ovary syndrome on cardiovascular risk
Rizzo, M., Berneis, K. K., Spinas, G. A., Rini, G. B., & Carmina, E. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.070 · Cited by 67
CONCERN: Does ovary need D-chiro-inositol?
Isabella, R., & Raffone, E. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-14 · Cited by 67
Cardiometabolic risk in polycystic ovary syndrome
Bajuk Studen, K., & Pfeifer, M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0129 · Cited by 64
Studen, K. B., Šebeštjen, M., Pfeifer, M., & Preželj, J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0709 · Cited by 62
Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature
Javier, B., Magdalena, B., Roberto, S., Ricardo, L., Rodrigo, Z., Jaime, P., Erwin, B., & Luis, C. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31595-9 · Cited by 62
Myo-Inositol in the Treatment of Teenagers Affected by PCOS
Pkhaladze, L., Barbakadze, L., & Kvashilava, N. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1473612 · Cited by 62
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism
Lakryc, E. M., Motta, E. L. A., Soares, J. M., Haidar, M. A., de Lima, G. R., & Baracat, E. C. (2003) · Gynecological Endocrinology · doi:10.1080/713603187 · Cited by 60
Fruzzetti, F., & Cagnacci, A. (2018) · Open Access Journal of Contraception · doi:10.2147/oajc.s179673 · Cited by 59
Hurliman, A. K., Brown, J. K., Maille, N., Mandalà, M., Casson, P. R., & Osol, G. (2015) · Endocrinology · doi:10.1210/en.2015-1159 · Cited by 57
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
Ciotta, L., Calogero, A. E., Farina, M., De Leo, V., La Marca, A., & Cianci, A. (2001) · Human Reproduction · doi:10.1093/humrep/16.10.2066 · Cited by 55
Ferjan, S., Janež, A., & Jensterle, M. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0027 · Cited by 55
Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients
Ismail, F. F., Meah, N., de Carvalho, L. T., Bhoyrul, B., Wall, D. R., & Sinclair, R. D. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.034 · Cited by 54
Spironolactone in the treatment of polycystic ovary syndrome
Armanini, D., Andrisani, A., Bordin, L., & Sabbadin, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215430 · Cited by 53 · cited 1×
“The addition of spironolactone to COCs has been proposed not only to enhance the antiandrogen effects, but also to reduce short- and long-term side effects related to RAAS activation [58].”
BackgroundSelf-citationKohler, C., Tschumi, K., Bodmer, C., Schneiter, M., & Birkhaeuser, M. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701214463 · Cited by 51
Polycystic ovary syndrome: an endocrine and metabolic disease
Scarpitta, A. M., & Sinagra, D. (2000) · Gynecological Endocrinology · doi:10.3109/09513590009167709 · Cited by 51
de Medeiros, S. F. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-017-0313-y · Cited by 51
Gateva, A., Unfer, V., & Kamenov, Z. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1421632 · Cited by 51
Metabolic impact of combined hormonal contraceptives containing estradiol
Grandi, G., Napolitano, A., & Cagnacci, A. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1190832 · Cited by 50
Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism
Bastianelli, C., Farris, M., Rosato, E., Brosens, I., & Benagiano, G. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1271708 · Cited by 50
The efficacy and use of finasteride in women: a systematic review
Hu, A. C., Chapman, L. W., & Mesinkovska, N. A. (2019) · International Journal of Dermatology · doi:10.1111/ijd.14370 · Cited by 48
Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome
Falsetti, L., Fusco, D. D., Eleftheriou, G., & Rosina, B. (1997) · Gynecological Endocrinology · doi:10.3109/09513599709152542 · Cited by 47
Armeni, E., Stamatelopoulos, K., Rizos, D., Georgiopoulos, G., Kazani, M., Kazani, A., Kolyviras, A., Stellos, K., Panoulis, K., Alexandrou, A., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283630362 · Cited by 46
Armanini, D., Bordin, L., Donà, G., Sabbadin, C., Bakdounes, L., Ragazzi, E., Giorgino, F. L., & Fiore, C. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.010 · Cited by 45
Self-citationThiazolidinediones for Treatment of Polycystic Ovary Syndrome
Stout, D. L., & Fugate, S. E. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.244.56943 · Cited by 45
Tang, L., Yuan, L., Yang, G., Wang, F., Fu, M., Chen, M., & Liu, D. (2019) · Clinical Endocrinology · doi:10.1111/cen.14056 · Cited by 45
Ibanez, L. (2004) · Human Reproduction · doi:10.1093/humrep/deh329 · Cited by 44
Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections · doi:10.1530/ec-16-0113 · Cited by 44
Bahceci, M., Tuzcu, A., Canoruc, N., Tuzun, Y., Kidir, V., & Aslan, C. (2004) · Hormone Research in Paediatrics · doi:10.1159/000081973 · Cited by 43
Hypertension in Polycystic Ovary Syndrome: Novel Insights
Macut, D., Mladenović, V., Bjekić-Macut, J., Livadas, S., Stanojlović, O., Hrnčić, D., Rašić-Marković, A., Milutinović, D. V., & Andrić, Z. (2020) · Current Hypertension Reviews · doi:10.2174/1573402115666190531071422 · Cited by 42
Genazzani, A. D., Prati, A., Marchini, F., Petrillo, T., Napolitano, A., & Simoncini, T. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640200 · Cited by 42
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin, J. K., Nian, H., Celedonio, J. E., Wright, P., & Brown, N. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz028 · Cited by 42
Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome
Banaszewska, B., Pawelczyk, L. A., & Spaczyński, R. (2019) · Reproductive Biology · doi:10.1016/j.repbio.2019.09.006 · Cited by 42
Cardio‐metabolic risk factors among young infertile women: a systematic review and meta‐analysis
Mulder, C. L., Lassi, Z. S., Grieger, J. A., Alì, A., Jankovic‐Karasoulos, T., Roberts, C. T., & Andraweera, P. H. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16171 · Cited by 42
Moretti, C., Guccione, L., Di Giacinto, P., Simonelli, I., Exacoustos, C., Toscano, V., Motta, C., De Leo, V., Petraglia, F., & Lenzi, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01186 · Cited by 40
Metformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0311-1 · Cited by 39
Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism
Leo, V. D., Fruzzetti, F., Musacchio, M. C., Scolaro, V., Sabatino, A. D., & Morgante, G. (2013) · Contraception · doi:10.1016/j.contraception.2012.09.003 · Cited by 39
Tao, T., Wu, P., Wang, Y., & Liu, W. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0243-5 · Cited by 38
Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis
Bonacina, F., Dalt, L. D., Catapano, A. L., & Norata, G. D. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100918 · Cited by 38
Spironolactone for Hirsutism in Polycystic Ovary Syndrome
Christy, N. A., Franks, A. S., & Cross, L. B. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g025 · Cited by 37
AJOSSA, S., Guerriero, S., Paoletti, A. M., Orrù, M., & Melis, G. B. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03101-1 · Cited by 36
Ferjan, S., Janez, A., & Jensterle, M. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0095 · Cited by 36
Safety of antiandrogen therapy for treating prostate cancer
Ricci, F., Buzzatti, G., RUBAGOTTI, A., & Boccardo, F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.966686 · Cited by 35
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903190699 · Cited by 35
Sahin, I., Serter, R., Karakurt, F., Demirbas, B., Culha, C., Taskapan, C., Kosar, F., & Aral, Y. (2004) · Gynecological Endocrinology · doi:10.1080/09513590400004736 · Cited by 34
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00189 · Cited by 33
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
Self-citationAlbu, A. I., Radian, S., Fica, S. V., & Barbu, C. G. (2014) · Endocrine · doi:10.1007/s12020-014-0340-9 · Cited by 32
Long-term safety and tolerability of flutamide for the treatment of hirsutism
Castelo‐Branco, C., Moyano, D., Gómez, O., & Balasch, J. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.046 · Cited by 32
Antihypertensive effects of flutamide in rats that are exposed to a low-protein diet in utero
Gangula, P. R., Reed, L. C., & Yallampalli, C. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.09.008 · Cited by 31
Yildizhan, R., Gokce, A. I., Yildizhan, B., & Cim, N. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1006187 · Cited by 31
Fruzzetti, F., Capozzi, A., Canu, A., & Lello, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540573 · Cited by 31
Effects of Acarbose on Polycystic Ovary Syndrome: A Meta-analysis
Zhang, Y.-Y., Hou, L.-Q., & Zhao, T.-Y. (2014) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0034-1375676 · Cited by 30
Paradisi, R., & Venturoli, S. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0100 · Cited by 30
Esmaeilzadeh, S., Gholinezhad, M., & Ghadimi, R. (2017) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_74_16 · Cited by 30
Flutamide-induced hepatotoxicity: ethical and scientific issues.
Giorgetti, R., Muzio, M. D., Giorgetti, A., Girolami, D., Borgia, L., & Tagliabracci, A. (2017) · PubMed · Cited by 29
Tedesco, S., Adorni, M. P., Ronda, N., Cappellari, R., Mioni, R., Barbot, M., Pinelli, S., Plebani, M., Bolego, C., Scaroni, C. M., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01911-2 · Cited by 29
Self-citationSathyapalan, T., Hobkirk, J., Javed, Z., Carroll, S., Coady, A., Pemberton, P. W., Smith, A., Cianflone, K., & Atkin, S. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00394 · Cited by 27
Carlo, C. D., Gargano, V., Sparice, S., Tommaselli, G. A., Bifulco, G., & Nappi, C. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.831834 · Cited by 26
Dokras, A., Playford, M. P., Kris‐Etherton, P. M., Kunselman, A. R., Stetter, C., Williams, N. I., Gnatuk, C. L., Estes, S. J., Sarwer, D. B., Allison, K. C., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13310 · Cited by 24
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0173 · Cited by 24
Combined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Vlieg, A. V. H., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813 · Cited by 24
Tuğrul, S., Kutlu, T., Pekin, O., Bağlam, E., Kiyak, H. A., & Oral, Ö. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1326 · Cited by 23
Low-dose flutamide for hirsutism: into the limelight, at last
de Zegher, F., & Ibáñez, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.119 · Cited by 23
Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
Sabbadin, C., Andrisani, A., Ambrosini, G., Bordin, L., Donà, G., Manso, J., Ceccato, F., Scaroni, C., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00575 · Cited by 22
Self-citationAlmalki, H. H., Alshibani, T. M., Alhifany, A. A., & Almohammed, O. A. (2020) · BMC Women s Health · doi:10.1186/s12905-020-00919-5 · Cited by 22
Froese, N., Wang, H., Zwadlo, C., Wang, Y., Grund, A., Gigina, A., Hofmann, M., Kilian, K., Scharf, G. M., Korf‐Klingebiel, M., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.08.011 · Cited by 21
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Romualdi, D., Versace, V., & Lanzone, A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120908709 · Cited by 20
Saslow, L. R., & Aikens, J. E. (2020) · JMIR Formative Research · doi:10.2196/17126 · Cited by 20
Comparison of Finasteride, Metformin, and Finasteride Plus Metformin in PCOS
Diri, H., Bayram, F., Simsek, Y., Caliskan, Z., & Kocer, D. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.84 · Cited by 19
Penna, I. A. D. A., Canella, P. R. B., Vieira, C. S., de Sá, M. F. S., dos Reis, R. M., & Ferriani, R. A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.073 · Cited by 17
Baldani, D. P., Skrgatic, L., Ougouag, R., & Kasum, M. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1381681 · Cited by 17
Erratum to: Metformin in women with PCOS, Pros
Pasquali, R. (2014) · Endocrine · doi:10.1007/s12020-014-0403-y · Cited by 13
Mioni, R., Cà, A. D., Turra, J., Azzolini, S., Xamin, N., Bleve, L., Maffei, P., Vettor, R., & Fallo, F. (2016) · Endocrine · doi:10.1007/s12020-016-0958-x · Cited by 13
Self-citationCedeno, J., Mendoza, S. G., Velázquez-Maldonado, E., Nucete, H., Speirs, J., & Glueck, C. J. (1990) · Metabolism · doi:10.1016/0026-0495(90)90010-a · Cited by 12
Sathyapalan, T., Coady, A., Kilpatrick, E. S., & Atkin, S. L. (2017) · Endocrine Connections · doi:10.1530/ec-17-0217 · Cited by 11
Generali, J. A., & Cada, D. J. (2014) · Hospital Pharmacy · doi:10.1310/hpj4906-517 · Cited by 10
Gidwani, S., Phelan, N., McGill, J. B., McGowan, A. N., O’Connor, A. S., Young, I. S., Gibney, J., & McEneny, J. (2014) · Human Reproduction · doi:10.1093/humrep/deu115 · Cited by 8
Vascular compliance in women with polycystic ovary syndrome treated with spironolactone
Muneyyirci‐Delale, O., Co, S., & Winer, N. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13385 · Cited by 6
The gender-specific clinical pharmacology of statins: an update
Cignarella, A. (2018) · Padua Research Archive (University of Padova) · doi:10.1723/3013.30116 · Cited by 3
Self-citationSpina, V., Camilli, S., Fabiani, C., et al. (2019) · IRIS Research product catalog (Sapienza University of Rome) · doi:10.14660/2385-0868-128
Research works printed but not linked: 1
- Scambia, 2019, The role of inositols in PCOS–opinion paper, Ital. J. Gynecol. Obstet., 31, 87
Cited by
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“Recent studies have also evaluated the effects of other insulin sensitizer drugs, wellknown and prescribed for diabetes mellitus type 2, such as incretin mimetics and sodium– glucose co-transporter type 2 inhibitors (SGLT2-i), which could be probably more effective on certain comorbidities, such as obesity and cardiov…”
BackgroundInfluentialSelf-citationPharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 65
Self-citationLo, A., Lo, C. C. W., & Oliver‐Williams, C. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead061 · Cited by 34
Rani, R., Chitme, H. R., Kukreti, N., Pant, P., Abdel‐Wahab, B. A., Khateeb, M. M., Habeeb, M. S., & Bakir, M. B. (2023) · Nutrients · doi:10.3390/nu15102238 · Cited by 34
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Metadata
- Authors
- Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C.
- Affiliations
- University of Padua (IT)
- AULSS 2 Marca Trevigiana (IT)
- Corresponding author
- Cignarella, Andrea
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-12-15
- Volume
- 21
- Issue
- 24
- Pages
- 9554
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7765466
- OpenAlex
- W3112398518
- Cited by
- 36
- References
- 190
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 4
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, cardiometabolic risk, hyperandrogenism, insulin resistance, metformin, myo-inositol, mineralocorticoid receptor antagonists, androgen receptor antagonists, 5-alpha reductase inhibitors, synthetic progestins, combined oral contraceptives, cholesterol efflux capacity, macrophage activation, cardiovascular risk, disease phenotypes
- MeSH terms
- Adult, Androgen Antagonists, Cardiovascular Diseases, Contraceptives, Oral, Disease Susceptibility, Female, Humans, Polycystic Ovary Syndrome, Risk Factors, Biomarkers, Outcome Assessment, Health Care, Risk Assessment, Chemoprevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.